跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Hospira Irinotecan (Irinotecan Hydrochloride) 20mg/mL concentrate for solution for infusion 40mg/2mL vial. - TGA Drug Approval Details
Approvals
/
TGA
/
Hospira Irinotecan (Irinotecan Hydrochloride) 20mg/mL concentrate for solution for infusion 40mg/2mL vial.
Approved
STANDARD
Hospira Irinotecan (Irinotecan Hydrochloride) 20mg/mL concentrate for solution for infusion 40mg/2mL vial.
Hospira Australia Pty Ltd
🇦🇺 Therapeutic Goods Administration
Approval Date
May 30, 2025
Approval ID
f5b1129434824272
Company
Hospira Australia Pty Ltd
Type
Standard
Approval Details
Approval Id
f5b1129434824272
Product Name
Hospira Irinotecan (Irinotecan Hydrochloride) 20mg/mL concentrate for solution for infusion 40mg/2mL vial.
Artg Id
106975
Artg Name
Hospira Irinotecan (Irinotecan Hydrochloride) 20mg/mL concentrate for solution for infusion 40mg/2mL vial.
Sponsor
Hospira Australia Pty Ltd
Company Detail Path
/organization/hospira-australia-pty-ltd
Artg Date
2004-08-19
Registration Type
Medicine
Therapeutic Good Type
Medicine
Licence Status
A
Licence Category
LIE
Active Ingredients
Approved
Quick Info
Agency
TGA
Country
🇦🇺
Approval Date
May 30, 2025
Approval ID
f5b1129434824272
Type
Standard
Back to TGA Approvals
